Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Public ClinicalTrials.gov record NCT01632904. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.
Study identification
- NCT ID
- NCT01632904
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2012 (Type not available)
- Primary completion
- Mar 2014 (Actual)
- Completion
- May 2016 (Actual)
- Last update posted
- Nov 14, 2017
2012 – 2016
United States locations
- U.S. sites
- 51
- U.S. states
- 28
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Fayetteville | Arkansas | — | — |
| Not listed | Burbank | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Stamford | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Boynton Beach | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Niles | Illinois | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Ames | Iowa | — | — |
| Not listed | Westwood | Kansas | — | — |
| Not listed | Alexandria | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Southfield | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Henderson | Nevada | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | East Orange | New Jersey | — | — |
| Not listed | Morristown | New Jersey | — | — |
| Not listed | Somerville | New Jersey | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Armonk | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Canton | Ohio | — | — |
| Not listed | Bethlehem | Pennsylvania | USA | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Amarillo | Texas | — | — |
| Not listed | Bedford | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Garland | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Longview | Texas | — | — |
| Not listed | Midland | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Alexandria | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01632904, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01632904 live on ClinicalTrials.gov.